Data & Analysis
Data & Analysis · page 3
- Data & Analysis
Public Data is No Longer Enough to Understand the German Medical Cannabis Market
Germany’s medical cannabis market, which has long been the engine powering Europe’s wider market growth, once again finds itself in a state of flux.
- Supply Chain
UK Medical Cannabis Imports Hit 30 Tonnes as Canadian Producers Bypass European Processors
Canadian producers shipped 17,067kg of medical cannabis directly to the UK in 2025, more than six times the 2,578kg recorded the year before, according to the latest official Home Office data seen by Business of Cannabis.
- Supply Chain
International News Round-Up: Australian medical cannabis sales plummet, smokable ban looms in Israel and more…
AUSTRALIAN medical cannabis sales tanked by over a quarter in the second half of 2025, following a clampdown on the previous ‘profit before patient’ model A report from the Penington Institute shows that medical cannabis sales peaked in the second half of 2024 at 3.72m units before falling to 2.65m units in the second half…
- Investment & Finance
The Fight for Cannabis Rescheduling Is Far From Over
Last week’s rescheduling announcement came as a surprise to many, not least to us here at Business of Cannabis.
- Industry Trends
Does the UK Media’s Cannabis Coverage Reflect Public Opinion? The Data Says No
This morning, the latest in a now-weekly series of stories in the British mainstream press was published in The Times, for the second week in a row taking aim at the advertising practices of some of the UK’s largest clinics.
- Industry Trends
Germany Now Represents 62% of Canadian Cannabis Flower Exports as Portugal’s Share Collapses
Canadian cannabis exports totalled CA$51.6 million in February 2026 across the three main cannabis HS codes tracked in export data, up 8.7% on the same month a year earlier.
- UK & Europe
Züri Can Extended By Two Years As Results Point To Black Market Deterrence
Zurich’s municipal parliament has voted to extend its flagship adult-use cannabis pilot, Züri Can, by a further two years to October 2028, and to provide an additional CHF 800,000 in funding, in a 101-13 vote that laid bare the fault lines in Swiss cannabis politics.
- Industry Trends
Germany’s Cannabis Reform Shows No Signs of Harm its Critics Predicted, Government Mandated Data Shows
On the second anniversary of Germany’s landmark Cannabis Act (CanG) coming into force, the most comprehensive data and analysis of its impact to date has been published.
- Data & Analysis
Stable Consumption, Falling Arrests: Germany’s Cannabis Landscape 2-Years On
Next week will mark the second anniversary of the implementation of Germany’s landmark Cannabis Act (CanG), which came into force on April 01, 2024.
- Industry Trends
New Report: UK and Germany Medical Cannabis Markets Both Double in 2025
The UK and Germany’s medical cannabis markets both more than doubled in size throughout 2025, once again cementing the countries as the engine behind European market growth.
- Clinical Research
Beyond the Abstract: What the Landmark Lancet Psychiatry Cannabinoid Review Shows
A major new systematic review has concluded that the available evidence rarely justifies the routine prescribing of cannabinoids for mental health conditions and substance use disorders.
- Data & Analysis
Diverging Cannabis Usage Trends Highlight Uneven Impact Of Europe’s Policy Landscape
Cannabis remained Europe’s most commonly used drug in 2025, according to new wastewater analysis from the European Union Drugs Agency (EUDA), suggesting around 8.4% of European adults have consumed cannabis within the last year.
